築友智造科技(00726.HK)上半年預製裝配式建築構件及產品銷售合同額同比增369.46%
格隆匯7月21日丨築友智造科技(00726.HK)發佈公吿,集團預製裝配式建築構件及產品的銷售合同額相較去年均已顯著增加。集團預製裝配式建築構件及產品的銷售合同額由截至2020年6月30日止半年度約3.34億人民幣增加約369.46%至截至2021年6月30日止半年度約15.68億人民幣。
公司執行董事郭衞強先生表示:“我們對中國受中央政府大力支持的預製裝配式建築產業充滿信心。預期中國預製裝配式建築產業的發展規模將持續取得迅猛增長。”集團將繼續增加其產量,以滿足預製裝配式建築構件及產品日益增長的市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.